作者的详细信息

Саржевский, Владислав Олегович

期 栏目 标题 文件
卷 22, 编号 2 (2020) Conference Proceedings Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic PDF
(Rus)
卷 22, 编号 2 (2020) Original Article High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience PDF
(Rus)
卷 22, 编号 4 (2020) CLINICAL ONCOLOGY Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy PDF
(Rus)
卷 23, 编号 1 (2021) CLINICAL ONCOLOGY The role of positron emission tomography in different types of malignant lymphomas: the results of 2020 PDF
(Rus)
卷 23, 编号 3 (2021) CLINICAL ONCOLOGY The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous? PDF
(Rus)
卷 24, 编号 1 (2022) CLINICAL ONCOLOGY Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study PDF
(Rus)
卷 25, 编号 4 (2023) CLINICAL ONCOLOGY Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study PDF
(Rus)

##common.cookie##